Bevacizumab in combination with irinotecan plus fluorouracil plus leucovorin chemotherapy prolongs survival but increases adverse events in people with metastatic colorectal cancer

Michael A. Choti

doi:10.1016/j.ctrv.2004.09.003

Bevacizumab in combination with irinotecan plus fluorouracil plus leucovorin chemotherapy prolongs survival but increases adverse events in people with metastatic colorectal cancer

Michael A. Choti

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	715-720
Number of pages	6
Journal	Cancer Treatment Reviews
Volume	30
Issue number	8
DOIs	https://doi.org/10.1016/j.ctrv.2004.09.003
State	Published - Dec 2004

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging

Access to Document

10.1016/j.ctrv.2004.09.003

Cite this

@article{2b6f8bed5b0f4046840072b633e7b0a7,

title = "Bevacizumab in combination with irinotecan plus fluorouracil plus leucovorin chemotherapy prolongs survival but increases adverse events in people with metastatic colorectal cancer",

author = "Choti, {Michael A.}",

year = "2004",

month = dec,

doi = "10.1016/j.ctrv.2004.09.003",

language = "English (US)",

volume = "30",

pages = "715--720",

journal = "Cancer Treatment Reviews",

issn = "0305-7372",

publisher = "W.B. Saunders Ltd",

number = "8",

}

TY - JOUR

T1 - Bevacizumab in combination with irinotecan plus fluorouracil plus leucovorin chemotherapy prolongs survival but increases adverse events in people with metastatic colorectal cancer

AU - Choti, Michael A.

PY - 2004/12

Y1 - 2004/12

UR - http://www.scopus.com/inward/record.url?scp=8644249844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8644249844&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2004.09.003

DO - 10.1016/j.ctrv.2004.09.003

M3 - Comment/debate

C2 - 15541582

AN - SCOPUS:8644249844

SN - 0305-7372

VL - 30

SP - 715

EP - 720

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

IS - 8

ER -

Bevacizumab in combination with irinotecan plus fluorouracil plus leucovorin chemotherapy prolongs survival but increases adverse events in people with metastatic colorectal cancer

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this